Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

TP53 mutant MDM2-amplified cell lines selected for resistance to MDM2-p53 binding antagonists retain sensitivity to ionizing radiation.

Oncotarget - 19 Jul 2016

Drummond Catherine J, Esfandiari Arman, Liu Junfeng, Lu Xiaohong, Hutton Claire, Jackson Jennifer, Bennaceur Karim, Xu Qing, Makimanejavali Aditya Rao, Del Bello Fabio, Piergentili Alessandro, Newell David R, Hardcastle Ian R, Griffin Roger J, Lunec John

Abstract excerpt

Non-genotoxic reactivation of the p53 pathway by MDM2-p53 binding antagonists is an attractive treatment strategy for wild-type TP53 cancers. To determine how resistance to MDM2/p53 binding antagonists might develop, SJSA-1 and NGP cells were exposed to growth inhibitory concentrations of chemically distinct MDM2 inhibitors, Nutlin-3 and MI-63, and clonal resistant cell lines generated. The p53 mediated responses...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cell Line, Tumor
Share to Drug Resistance, Neoplasm

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to MDM2 gene

Share to Mutation

Share to Proto-Oncogene Proteins c-mdm2

Share to Tumor Suppressor Protein p53

Source

Open in PubMed Open full text

Identifiers

PMID: 27323823
DOI: 10.18632/oncotarget.10073
PMCID: PMC5216791

Genes

MDM2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

TP53 mutant MDM2-amplified cell lines selected for resistance to MDM2-p53 binding antagonists retain sensitivity to ionizing radiation.PMID 27323823Read ↗

Acquisition of p53 mutations in response to the non-genotoxic p53 activator Nutlin-3.Semantic proximity Read ↗

Nutlins and Ionizing Radiation in Cancer TherapySemantic proximity Read ↗

Resistance mechanisms to inhibitors of p53-MDM2 interactions in cancer therapy: can we overcome them?Semantic proximity Read ↗

Adaptation of cancer cells from different entities to the MDM2 inhibitor nutlin-3 results in the emergence of p53-mutated multi-drug-resistant cancer cells.Semantic proximity Read ↗

TP53 mutations increase radioresistance in rhabdomyosarcoma and Ewing sarcoma.Semantic proximity Read ↗

Prolonged Idasanutlin (RG7388) Treatment Leads to the Generation of p53-Mutated CellsSemantic proximity Read ↗

Small-Molecule Antagonists of p53-MDM2 Binding: Research Tools and Potential TherapeuticsSemantic proximity Read ↗

Human neuroblastoma cells with acquired resistance to the p53 activator RITA retain functional p53 and sensitivity to other p53 activating agents.Semantic proximity Read ↗

Pharmacologically Increasing Mdm2 Inhibits DNA Repair and Cooperates with Genotoxic Agents to Kill p53-Inactivated Ovarian Cancer CellsSemantic proximity Read ↗

<i>TP53</i> mutations and drug sensitivity in acute myeloid leukaemia cells with acquired MDM2 inhibitor resistanceSemantic proximity Read ↗

MDM2 inhibitor Nutlin-3a suppresses proliferation and promotes apoptosis in osteosarcoma cellsSemantic proximity Read ↗

Targeting p63 Upregulation Abrogates Resistance to MAPK Inhibitors in Melanoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.